

# **CV 2024**

## **1. General information**

Dr. Jose Alfredo Gómez Puerta, MD, PhD, MPH

### **Current position**

- Head of Rheumatology Department Hospital Clínic, Barcelona
- Associate Professor, Universitat de Barcelona, Spain

### **Academic background**

- Research Fellow, Lupus Unit, St Thomas' Hospital, Londres, Reino Unido, 1997 y 2001
- Specialist in Internal Medicine, 2002, University Pontificia Bolivariana, Medellín, Colombia
- Specialist in Rheumatology, Hospital Clinic, Barcelona 2008
- Doctor in Medicine, Universitat de Barcelona, 2007
- Master in Autoimmune Diseases, Universitat de Barcelona, 2012
- Post-doctoral Research Fellow, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, 2011-2014
- Master in Public Health, Harvard School of Public Health, 2014

**Research areas:** Autoimmune diseases, inflammatory arthritis, biologic therapies, immunotherapy

## **2. Publications**

Indexed journals: 143

**H index:** 38

<https://pubmed.ncbi.nlm.nih.gov/?term=GOMEZ+PUERTA+J&sort=date>

**ORCID:** 0000-0001-8177-702X

### **Recent publications in SLE**

1. 2023 ACR/EULAR antiphospholipid syndrome classification criteria.

Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, Amoura Z, Andrade D, Andreoli L, Artim-Esen B, Atsumi T, Avcin T, Belmont HM, Bertolaccini ML, Branch DW, Carvalheiras G, Casini A, Cervera R, Cohen H, Costedoat-Chalumeau N, Crowther

M, de Jesús G, Delluc A, Desai S, Sancho M, Devreese KM, Diz-Kucukkaya R, Duarte-García A, Frances C, Garcia D, Gris JC, Jordan N, Leaf RK, Kello N, Knight JS, Laskin C, Lee AI, Legault K, Levine SR, Levy RA, Limper M, Lockshin MD, Mayer-Pickel K, Musial J, Meroni PL, Orsolini G, Ortell TL, Pengo V, Petri M, Pons-Estel G, **Gómez-Puerta JA**, Raimboug Q, Roubey R, Sanna G, Seshan SV, Sciascia S, Tektonidou MG, Tincani A, Wahl D, Willis R, Yelnik C, Zulily C, Guillemin F, Costenbader K, Erkan D; ACR/EULAR APS Classification Criteria Collaborators. *Ann Rheum Dis.* 2023 Oct;82(10):1258-1270. doi: 10.1136/ard-2023-224609

2. From systemic lupus erythematosus to lupus nephritis: The evolving road to targeted therapies. Xipell M, Lledó GM, Egan AC, Tamirou F, Del Castillo CS, Rovira J, **Gómez-Puerta JA**, García-Herrera A, Cervera R, Kronbichler A, Jayne DRW, Anders HJ, Houssiau F, Espinosa G, Quintana LF. *Autoimmun Rev.* 2023 Oct;22(10):103404. doi: 10.1016/j.autrev.2023.103404.

3. Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines.

Lledó GM, Xipell M, García-Herrera A, Bueno L, Cervera R, Galindo M, **Gómez-Puerta JA**, Morales E, Praga M, Rojas JE, Ruiz-Irastorza G, Pernaute OS, Jayne D, Espinosa G, Quintana LF; Multidisciplinary Group for the Study of Lupus Nephritis.

*Eur J Intern Med.* 2022 May;99:19-21. doi: 10.1016/j.ejim.2022.03.016. Epub 2022 Mar 19.

3. Bilateral striopallidal calcinosis secondary to systemic lupus erythematosus.

Betancur JF, **Gómez-Puerta JA**, Llano JF, López-Ochoa GA, Ramirez B, Martinez OD.

*Radiol Case Rep.* 2022 Apr 25;17(6):2257-2261. doi: 10.1016/j.radcr.2022.03.114. eCollection 2022 Jun.

4. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study.

Izadi Z, Gianfrancesco MA, Schmajuk G, Jacobsohn L, Katz P, Rush S, Ja C, Taylor T, Shidara K, Danila MI, Wysham KD, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, Carmona L, Lawson-Tovey S, Kearsley-Fleet L, Schaefer M, Al-Emadi S, Sparks JA, Hsu TY, Patel NJ, Wise L, Gilbert E, Duarte-García A, Valenzuela-Almada MO, Ugarte-Gil MF, Ljung L, Scirè CA, Carrara G, Hachulla E, Richez C, Cacoub P, Thomas T, Santos MJ, Bernardes M, Hasseli R, Regierer A, Schulze-Koops H, Müller-Ladner U, Pons-Estel G, Tanten R, Nieto RE, Pisoni CN, Tissera YS, Xavier R, Lopes Marques CD, Pileggi GCS, Robinson PC, Machado PM, Sirotich E, Liew JW, Hausmann JS, Sufka P, Grainger R, Bhana S, Gore-Massy M, Wallace ZS, Yazdany J; COVID-19 Global Rheumatology Alliance Registry.

Lancet Rheumatol. 2022 Jul 25. doi: 10.1016/S2665-9913(22)00192-8.

5. Controversies in Systemic Lupus Erythematosus: Are We Treating Our Patients Adequately?

Porta SV, Ugarte-Gil MF, García-de la Torre I, Bonfá E, **Gómez-Puerta JA**, Arnaud L, Cardiel MH, Alarcón GS, Pons-Estel BA, Pons-Estel G.

J Clin Rheumatol. 2021 Nov 23. doi: 10.1097/RHU.0000000000001803. Online ahead of print.

6. A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group.

**Gómez-Puerta JA**, Pons-Estel GJ, Quintana R, Nieto R, Serrano Morales RM, Harvey GB, et al. Lupus. 2021 Jan 28:961203320988586. doi: 10.1177/0961203320988586. Online ahead of print.

7. Urinary levels of ceruloplasmin and monocyte chemoattractant protein-1 correlate with extra-capillary proliferation and chronic damage in patients with lupus nephritis.

Urrego-Callejas T, Álvarez SS, Arias LF, Reyes BO, Vanegas-García AL, González LA, Muñoz-Vahos CH, Vásquez G, Quintana LF, **Gómez-Puerta JA**.

Clin Rheumatol. 2021 May;40(5):1853-1859. doi: 10.1007/s10067-020-05454-0. Epub 2020 Oct 20.

8. Clinical practice guidelines and recommendations for the management of patients with systemic lupus erythematosus: a critical comparison.

Izcovich A, Alarcón GS, **Gómez-Puerta JA**, Pons-Estel GJ, Ugarte-Gil MF, Cardiel MH, Pons-Estel BA; GLADEL study group.

Rheumatology (Oxford). 2020 Dec 1;59(12):e165-e168. doi: 10.1093/rheumatology/keaa468.

9. A comparative study on clinical and serological characteristics between patients with rhupus and those with systemic lupus erythematosus and rheumatoid arthritis.

Frade-Sosa B, Narváez J, Salman-Monte TC, Castellanos-Moreira R, Ortiz-Santamaría V, Torrente-Segarra V, Castellvi I, Magallares B, Reina D, Minguez S, Sallés M, Manrique de Lara MG, Ordoñez S, Riera E, Schur PH, **Gómez-Puerta JA**.

Lupus. 2020 Sep;29(10):1216-1226. doi: 10.1177/0961203320938456. Epub 2020 Jul 6.

10. Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort.

Quintana R, Pons-Estel GJ, Roberts K, Sacnún M, Serrano R, Nieto R, Conti S, Gervasoni V, Catoggio LJ, Soriano ER, Scolnik M, García MA, Alvarellos A, Saurit V, Berbotto GA, Sato EI, Costallat LTL, Neto EFB, Bonfa E, Xavier RM, de Oliveira E Silva Montandon AC, Molina-Restrepo JF, Iglesias-Gamarra A, Guibert-Toledano M, Reyes-Llerena GA, Massardo L, Neira OJ, Cardiel MH, Barile-Fabris LA, Amigo MC, Silveira LH, Torre IG, Acevedo-Vásquez EM, Ugarte-Gil MF, Alfaro-Lozano JL, Segami MI, Chacón-Díaz R, Esteva-Spinetti MH, **Gómez-Puerta JA**, Alarcón GS, Pons-Estel BA.

Lupus. 2020 Aug;29(9):1140-1145. doi: 10.1177/0961203320935184. Epub 2020 Jun 30.

11. Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies.

Leatherwood C, Speyer CB, Feldman CH, D'Silva K, **Gómez-Puerta JA**, Hoover PJ, Waikar SS, McMahon GM, Rennke HG, Costenbader KH.

Semin Arthritis Rheum. 2019 Dec;49(3):396-404. doi: 10.1016/j.semarthrit.2019.06.002.

### **3. Clinical experience**

- Internal Medicine program 1999-2002
- Rheumatology Training program 2004-2008
- Early Rheumatoid arthritis Clinics from 2008 to 2011, Hospital Clínic, Barcelona, Spain
- Advisor Committee for biological therapies (2015-2017), Medicarte, Medellín, Colombia
- Inflammatory arthritis Clinic (1 session per week) (2017-2021), Hospital Clínic, Barcelona, Spain
- Active participation in clinical trials in RA (2017-2021), Hospital Clínic, Barcelona, Spain
- Autoimmune clinic, two sessions per week

#### **4. Additional merits**

- Member of GLADEL guidelines for the treatment of SLE (Methodology GRADE)
- Member of Recommendations for the prevention of infections in patients with autoimmune diseases, Sociedad Española de Reumatología (SER 2021)
- Member of Editorial team Lupus Journal
- Co PI Study “ Biomarkers in patients with Systemic lupus erythematosus in GLADEL 2.0 cohort”, study supported by PANLAR
- PI of the study “Disease Burden in Systemic Rheumatic diseases in Catalonia”
- Member of GLADEL 2.0, Latinamerican study group for SLE
- Coordinator of CAPICAT-MAS “Study group for autoimmune diseases and capillaroscopy of Catalan Society of Rheumatology”
- Member of Recommendations for the prevention of infections in patients with autoimmune diseases, Sociedad Española de Reumatología (SER 2021)
- Member of Executive committee of SLEuro (2022-2024)
- Member of OMERACT study group in SLE

#### **Brief summary**

Dr. Jose A. Gómez-Puerta is a specialist in Internal Medicine from the Universidad Pontificia Bolivariana, Medellín, Colombia, and a Rheumatologist at the Hospital Clinic of the University of Barcelona, Spain. He was awarded a Ph.D. in Biopathology by the University of Barcelona in 2008.

He received further training in the Rheumatology Unit of Guy's Hospital, London, UK, and the Lupus Unit, St. Thomas' Hospital, London, UK, in 1997 and 2001, respectively.

He also finished the Master in Autoimmune Diseases at Universidad de Barcelona and moved for an appointment as Post-Doctoral Research Fellow at Brigham and Women's Hospital at Harvard Medical School, Boston, USA from 2011 to 2014.

In 2014, Dr Gómez-Puerta obtained his degree in Master of Public Health at Harvard School of Public Health, Boston.USA.

His work has focused on the study of Autoimmune and immune mediated diseases and he has published more than 140 original papers, brief notes or reviews in peer-reviewed journals and over 200 communications in national and international meetings. He is co-investigator of GLADEL 2.0 study group, member of the executive committee of SLEuro and member of the stetting committe of ACR/EULAR for immune-mediated adverse events.

He is a member of the Catalan, Spanish, Colombian and honorary member of Argentinian and Chilean societies of Rheumatology and member of the American College of Rheumatology.

Currently, Dr Gómez-Puerta is the Head of Department of Rheumatology At Hospital Clinic, Barcelona and associate professor of Rheumatology at University of Barcelona, Spain